{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:50:12Z","timestamp":1792759812611,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,19]],"date-time":"2017-02-19T00:00:00Z","timestamp":1487462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.semarthrit.2017.02.001","type":"journal-article","created":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T13:32:02Z","timestamp":1486560722000},"page":"29-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["Switching biologics in the treatment of psoriatic arthritis"],"prefix":"10.1016","volume":"47","author":[{"given":"Joseph F.","family":"Merola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lockshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elinor A.","family":"Mody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2017.02.001_bib1","doi-asserted-by":"crossref","first-page":"176298","DOI":"10.1155\/2012\/176298","article-title":"Psoriatic arthritis: an update","volume":"2012","author":"Lloyd","year":"2012","journal-title":"Arthritis"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics","volume":"58","author":"Gottlieb","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib3","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Treatment recommendations for psoriatic arthritis","volume":"68","author":"Ritchlin","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib4","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl. 10","key":"10.1016\/j.semarthrit.2017.02.001_bib5","first-page":"S346","article-title":"Results of a randomised controlled trial comparing tight control of early psoriatic arthritis (TICOPA) with standard care: tight control improves outcome [abstract]","volume":"65","author":"Coates","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib6","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0140-6736(14)60299-3","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a multicentre, open-label, randomised controlled trial","volume":"383","author":"Coates","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib7","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/annrheumdis-2014-205490","article-title":"First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register","volume":"73","author":"Lie","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib8","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/rheumatology\/ket187","article-title":"The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics","volume":"52","author":"Coates","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","article-title":"European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies","volume":"71","author":"Gossec","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib10","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1517\/14712598.2014.967211","article-title":"Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity","volume":"14","author":"Lories","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib11","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/acr.22645","article-title":"Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial","volume":"67","author":"Kavanaugh","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib12","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/BOR.0000000000000151","article-title":"New treatment paradigms in psoriatic arthritis: an update on new therapeutics approved by the U.S. Food and Drug Administration","volume":"27","author":"Felquer","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib14","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3899\/jrheum.140647","article-title":"Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis","volume":"42","author":"Kavanaugh","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/2040622312459673","article-title":"Steps in the management of psoriatic arthritis: a guide for clinicians","volume":"3","author":"Cuchacovich","year":"2012","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib16","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.3899\/jrheum.140877","article-title":"Updated guidelines for the management of axial disease in psoriatic arthritis","volume":"41","author":"Nash","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib17","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1002\/art.34627","article-title":"Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study","volume":"64","author":"Schett","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib18","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.2174\/0929867322666150429111804","article-title":"An evidence-based review of the mechanism of action, efficacy, and safety of biologic therapies in the treatment of psoriasis and psoriatic arthritis","volume":"22","author":"Brezinski","year":"2015","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib19","first-page":"1167","article-title":"Consensus on a core set of domains for psoriatic arthritis","volume":"34","author":"Gladman","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib20","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3899\/jrheum.140876","article-title":"Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review","volume":"41","author":"Acosta Felquer","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib21","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3899\/jrheum.140878","article-title":"Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis","volume":"41","author":"Orbai","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jbspin.2014.05.003","article-title":"Current treatment of psoriatic arthritis: update based on a systematic literature review to establish French Society for Rheumatology (SFR) recommendations for managing spondyloarthritis","volume":"82","author":"Paccou","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib23","first-page":"26","article-title":"2011 Portuguese recommendations for the use of biological therapies in patients with psoriatic arthritis","volume":"37","author":"Machado","year":"2012","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2474-14-101","article-title":"The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis","volume":"14","author":"Coates","year":"2013","journal-title":"BMC Musculoskelet Disord"},{"issue":"Suppl. 2","key":"10.1016\/j.semarthrit.2017.02.001_bib26","doi-asserted-by":"crossref","first-page":"ii65","DOI":"10.1136\/ard.2004.031237","article-title":"Psoriasis assessment tools in clinical trials","volume":"64","author":"Feldman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib27","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12325-012-0037-5","article-title":"Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings","volume":"29","author":"Bonafede","year":"2012","journal-title":"Adv Ther"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib28","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/art.37876","article-title":"Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor \u03b1 inhibitor therapy: results from the Danish Nationwide DANBIO Registry","volume":"65","author":"Glintborg","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib29","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.30117","article-title":"Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry","volume":"63","author":"Glintborg","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib30","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/ard.2007.073569","article-title":"Switching tumour necrosis factor \u03b1 antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period","volume":"66","author":"Conti","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib31","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1136\/annrheumdis-2012-203018","article-title":"Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study","volume":"72","author":"Fagerli","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib32","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","article-title":"Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period","volume":"8","author":"Gomez-Reino","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/ard.2007.082925","article-title":"Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience","volume":"67","author":"Coates","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib34","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1186\/ar3054","article-title":"Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy","volume":"12","author":"Rudwaleit","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib35","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar2670","article-title":"Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register","volume":"11","author":"Saad","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s10354-010-0795-0","article-title":"Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis","volume":"160","author":"Haberhauer","year":"2010","journal-title":"Wien Med Wochenschr"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7861\/clinmedicine.14-1-95","article-title":"Effectiveness of switching between biologics in psoriatic arthritis\u2014results of a large regional survey","volume":"14","author":"Jani","year":"2014","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/09546634.2012.755255","article-title":"Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting","volume":"24","author":"Bonafede","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jbspin.2014.08.001","article-title":"Treatment response, drug survival and safety of anti-tumour necrosis factor \u03b1 therapy in 193 patients with psoriatic arthritis: a twelve-year real life experience","volume":"82","author":"Soubrier","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib40","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.clinthera.2013.07.328","article-title":"Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study","volume":"35","author":"Zhu","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib41","first-page":"2183","article-title":"Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data","volume":"32","author":"Delaunay","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib42","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib43","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib44","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib45","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ad.2013.04.003","article-title":"Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"104","author":"Puig","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib46","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ad.2014.11.005","article-title":"Expert recommendations on treating psoriasis in special circumstances","volume":"106","author":"Carrascosa","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4081\/reumatismo.2014.799","article-title":"Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?","volume":"66","author":"Rossini","year":"2015","journal-title":"Reumatismo"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib48","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1517\/14712598.2013.848194","article-title":"Immunogenicity of anti-TNF\u03b1 therapy in psoriasis: a clinical issue?","volume":"13","author":"De Simone","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/bjd.12941","article-title":"Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies","volume":"171","author":"Maybury","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib50","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jamadermatol.2014.3456","article-title":"Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation","volume":"151","author":"Armstrong","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib51","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3109\/09546631003801601","article-title":"Combination systemic therapies in psoriatic arthritis","volume":"22","author":"Daly","year":"2011","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib52","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12016-012-8301-7","article-title":"Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring","volume":"44","author":"Sivamani","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib53","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjd.12341","article-title":"Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study","volume":"169","author":"Mahil","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib54","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/08916934.2014.897333","article-title":"Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review","volume":"47","author":"Sozzani","year":"2014","journal-title":"Autoimmunity"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archdermatol.2011.1410","article-title":"Consensus guidelines for the management of plaque psoriasis","volume":"148","author":"Hsu","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","article-title":"Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients","volume":"9","author":"Wollina","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib57","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/bjd.13645","article-title":"Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients","volume":"173","author":"Jones","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib58","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jamadermatol.2013.5728","article-title":"Ustekinumab associated with flares of psoriatic arthritis","volume":"149","author":"Stamell","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib59","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/rheumatology\/kep270","article-title":"Adverse events and efficacy of TNF-\u03b1 blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients","volume":"48","author":"Aringer","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib60","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.autrev.2011.05.001","article-title":"Therapeutic blockade of TNF in patients with SLE-promising or crazy?","volume":"11","author":"Aringer","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib61","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaad.2014.10.038","article-title":"Treatment of coexistent psoriasis and lupus erythematosus","volume":"72","author":"Varada","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.autrev.2013.06.005","article-title":"Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-\u03b1 agents","volume":"13","author":"Fiorino","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib63","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ajg.2008.71","article-title":"Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy","volume":"104","author":"Kane","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib64","first-page":"S-149","article-title":"PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy [abstract]","volume":"142","author":"Mahadevan","year":"2012"},{"issue":"Suppl. 10","key":"10.1016\/j.semarthrit.2017.02.001_bib65","first-page":"S1874","article-title":"Pregnancy outcomes in women exposed to adalimumab: an update on the autoimmune diseases in pregnancy project [abstract]","volume":"63","author":"Johnson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib66","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.crohns.2010.05.001","article-title":"Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn\u05f3s disease","volume":"4","author":"Cheent","year":"2010","journal-title":"J Crohns Colitis"},{"issue":"Suppl. 3","key":"10.1016\/j.semarthrit.2017.02.001_bib67","doi-asserted-by":"crossref","first-page":"A426","DOI":"10.1136\/annrheumdis-2013-eular.1289","article-title":"Investigation into the binding affinity of certolizumab pegol to fcrn and functional consequences for fcrn-mediated transcytosis: comparison to infliximab, adalimumab and etanercept [abstract]","volume":"72","author":"Baker","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.semarthrit.2017.02.001_bib68","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1136\/annrheumdis-2015-eular.1788","article-title":"Pregnancy outcomes with trimesters of maternal exposure to certolizumab pegol: prospective and retrospective reports from safety surveillance [abstract]","volume":"74","author":"Clowse","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib69","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/rheumatology\/ket409","article-title":"Biologic therapies and pregnancy: the story so far","volume":"53","author":"Hyrich","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib70","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11926-012-0260-8","article-title":"Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives","volume":"14","author":"Boehncke","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib71","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.3899\/jrheum.140882","article-title":"Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations","volume":"41","author":"Ogdie","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib72","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/annrheumdis-2011-201194","article-title":"Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review","volume":"72","author":"Jamnitski","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib73","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jbspin.2014.02.005","article-title":"Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study","volume":"81","author":"Ramonda","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib74","unstructured":"The psoriasis, atherosclerosis, and cardiometabolic disease initiative (PACI), \u3008ClinicalTrials.gov\u3009. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01778569\u3009; 2016 [accessed 20.04.16]."},{"key":"10.1016\/j.semarthrit.2017.02.001_bib75","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cyto.2013.03.013","article-title":"IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities","volume":"62","author":"Golden","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib76","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/rheumatology\/kep354","article-title":"Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)","volume":"49","author":"Scarpato","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib77","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","article-title":"Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey","volume":"70","author":"Lebwohl","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib78","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1111\/jdv.13150","article-title":"Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey","volume":"29","author":"van de Kerkhof","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib79","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib80","unstructured":"A study of Ixekizumab (LY2439821) in participants with active psoriatic arthritis (SPIRIT-P2), \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02349295?term=spirit-p2&rank=1\u3009; 2016 [accessed 20.04.16]."},{"key":"10.1016\/j.semarthrit.2017.02.001_bib81","unstructured":"Study of efficacy, safety and effect on radiographic progession of Brodalumab in subjects with psoriatic arthritis (AMVISION-1), \u3008ClinicalTrials.gov\u3009. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02029495\u3009; 2016 [accessed 20.04.16]."},{"key":"10.1016\/j.semarthrit.2017.02.001_bib82","unstructured":"Study of efficacy and safety of Brodalumab in subjects with psoriatic arthritis (AMVISION-2), \u3008ClinicalTrials.gov\u3009. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02024646\u3009; 2016 [accessed 20.04.16]."},{"key":"10.1016\/j.semarthrit.2017.02.001_bib83","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib84","unstructured":"A multicenter study to evaluate the dose response based on the efficacy, safety and tolerability of Bimekizumab in subjects with active psoriatic arthritis which is a type of inflammatory arthritis, \u3008ClinicalTrials.gov\u3009. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02969525?term=Bimekizumab&rank=2\u3009; 2016 [accessed 13.12.16]."},{"key":"10.1016\/j.semarthrit.2017.02.001_bib85","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/BOR.0000000000000147","article-title":"Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis","volume":"27","author":"Mease","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib86","unstructured":"A study of Guselkumab in participants with moderate to severe plaque-type psoriasis and an inadequate response to Ustekinumab (NAVIGATE), \u3008ClinicalTrials.gov\u3009. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02203032\u3009; 2016 [accessed 16.05.16]."},{"key":"10.1016\/j.semarthrit.2017.02.001_bib87","unstructured":"Efficacy and safety study of Guselkumab in the treatment of participants with active psoriatic arthritis (PsA), \u3008ClinicalTrials.gov\u3009. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02319759\u3009; 2016 [accessed 16.05.16]."},{"key":"10.1016\/j.semarthrit.2017.02.001_bib88","unstructured":"BI 655066\/ABBV-066\/Risankizumab compared to placebo in patients with active psoriatic arthritis, \u3008ClinicalTrials.gov\u3009."},{"key":"10.1016\/j.semarthrit.2017.02.001_bib89","unstructured":"A study to evaluate the efficacy and safety\/tolerability of subcutaneous Tildrakizumab (SCH 900222\/MK-3222) in participants with moderate-to-severe chronic plaque psoriasis followed by a long-term extension study (MK-3222-011), \u3008ClinicalTrials.gov\u3009. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01729754\u3009; 2016 [accessed 16.05.16]."},{"issue":"Suppl. 10","key":"10.1016\/j.semarthrit.2017.02.001_bib90","volume":"68","author":"Gladman","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib91","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.30176","article-title":"Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib92","unstructured":"Efficacy and safety of subcutaneous Abatacept in adults with active psoriatic arthritis (ASTRAEA), \u3008ClinicalTrials.gov\u3009. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01860976\u3009; 2016 [accessed 20.04.16]."},{"key":"10.1016\/j.semarthrit.2017.02.001_bib93","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/rheumatology\/kes432","article-title":"Successful use of tocilizumab in a patient with psoriatic arthritis","volume":"52","author":"Hughes","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib94","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s10067-014-2603-5","article-title":"Efficacy of tocilizumab in a patient with refractory psoriatic arthritis","volume":"33","author":"Costa","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.001_bib95","doi-asserted-by":"crossref","first-page":"713618","DOI":"10.1155\/2012\/713618","article-title":"Pathological role of interleukin-6 in psoriatic arthritis","volume":"2012","author":"Ogata","year":"2012","journal-title":"Arthritis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216301573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216301573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T03:54:48Z","timestamp":1749959688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017216301573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0049017216301573"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.02.001","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching biologics in the treatment of psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}